Literature DB >> 11595348

Effect of ApoE and tau on age of onset of progressive supranuclear palsy and multiple system atrophy.

H R Morris1, A Schrag, U Nath, D Burn, N P Quinn, S Daniel, N W Wood, A J Lees.   

Abstract

In addition to allelic association between genetic polymorphisms and diseases, modulation of age of onset is a well recognised effect of disease susceptibility genes. The ApoE epsilon4 allele is associated with an earlier age of onset of sporadic and familial Alzheimer's disease. It has been suggested that the tau genotype influences the age of onset of progressive supranuclear palsy (PSP), a form of atypical parkinsonism caused by tau neurofibrillary tangle deposition. We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of atypical parkinsonism, multiple system atrophy (MSA). We have not found any effect of possession of the tau H1 haplotype or the ApoE epsilon4 allele on the age of onset of MSA or PSP.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11595348     DOI: 10.1016/s0304-3940(01)02190-5

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  12 in total

Review 1.  Epidemiological evidence on multiple system atrophy.

Authors:  N Vanacore
Journal:  J Neural Transm (Vienna)       Date:  2005-12       Impact factor: 3.575

Review 2.  Cellular factors modulating the mechanism of tau protein aggregation.

Authors:  Sarah N Fontaine; Jonathan J Sabbagh; Jeremy Baker; Carlos R Martinez-Licha; April Darling; Chad A Dickey
Journal:  Cell Mol Life Sci       Date:  2015-02-11       Impact factor: 9.261

Review 3.  A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward.

Authors:  Michaël E Belloy; Valerio Napolioni; Michael D Greicius
Journal:  Neuron       Date:  2019-03-06       Impact factor: 17.173

4.  Genetic players in multiple system atrophy: unfolding the nature of the beast.

Authors:  Sylvia Stemberger; Sonja W Scholz; Andrew B Singleton; Gregor K Wenning
Journal:  Neurobiol Aging       Date:  2011-05-24       Impact factor: 4.673

Review 5.  Tau and MAPT genetics in tauopathies and synucleinopathies.

Authors:  Etienne Leveille; Owen A Ross; Ziv Gan-Or
Journal:  Parkinsonism Relat Disord       Date:  2021-09-14       Impact factor: 4.402

6.  Cortical Alzheimer type pathology does not influence tau pathology in progressive supranuclear palsy.

Authors:  Kenichi Oshima; Dennis W Dickson
Journal:  Int J Clin Exp Pathol       Date:  2008-12-20

7.  Function and comorbidities of apolipoprotein e in Alzheimer's disease.

Authors:  Valérie Leduc; Dorothée Domenger; Louis De Beaumont; Daphnée Lalonde; Stéphanie Bélanger-Jasmin; Judes Poirier
Journal:  Int J Alzheimers Dis       Date:  2011-04-05

8.  Multiple system atrophy and apolipoprotein E.

Authors:  Kotaro Ogaki; Yuka A Martens; Michael G Heckman; Shunsuke Koga; Catherine Labbé; Oswaldo Lorenzo-Betancor; Anna I Wernick; Ronald L Walton; Alexandra I Soto; Emily R Vargas; Henrietta M Nielsen; Shinsuke Fujioka; Takahisa Kanekiyo; Ryan J Uitti; Jay A van Gerpen; William P Cheshire; Zbigniew K Wszolek; Phillip A Low; Wolfgang Singer; Dennis W Dickson; Guojun Bu; Owen A Ross
Journal:  Mov Disord       Date:  2018-02-14       Impact factor: 9.698

Review 9.  Genetics Underlying Atypical Parkinsonism and Related Neurodegenerative Disorders.

Authors:  Sonja W Scholz; Jose Bras
Journal:  Int J Mol Sci       Date:  2015-10-16       Impact factor: 5.923

10.  Assessment of APOE in atypical parkinsonism syndromes.

Authors:  Marya S Sabir; Cornelis Blauwendraat; Sarah Ahmed; Geidy E Serrano; Thomas G Beach; Matthew Perkins; Ann C Rice; Eliezer Masliah; Christopher M Morris; Lasse Pihlstrom; Alexander Pantelyat; Susan M Resnick; Mark R Cookson; Dena G Hernandez; Marilyn Albert; Ted M Dawson; Liana S Rosenthal; Henry Houlden; Olga Pletnikova; Juan Troncoso; Sonja W Scholz
Journal:  Neurobiol Dis       Date:  2019-02-21       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.